TrialNature medicine2022

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.

Sattva S Neelapu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.